Recro Pharma Inc.

NASDAQ: REPH · Real-Time Price · USD
2.09
-0.01 (-0.48%)
At close: Mar 22, 2022, 5:00 AM

Recro Pharma Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
94.64M 90.21M 75.36M
Cost of Revenue
76.5M 67.08M 55.54M
Gross Profit
18.14M 23.14M 19.82M
Operating Income
-3.57M -32.84M 3.76M
Interest Income
394K n/a n/a
Pretax Income
-13.14M -18.78M -11.37M
Net Income
-13.27M -19.88M -26.5M
Selling & General & Admin
21.02M 21.95M 18.37M
Research & Development
n/a n/a n/a
Other Expenses
687K 67.98M 1.04M
Operating Expenses
21.71M 89.94M 19.41M
Interest Expense
-9.96M -14.06M 15.13M
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
98.21M 157.01M 74.95M
Income Tax Expense
132K 1.1M 15.13M
Shares Outstanding (Basic)
95.23M 57.88M 51.42M
Shares Outstanding (Diluted)
95.23M 57.88M 51.42M
EPS (Basic)
-0.14 -0.34 -0.52
EPS (Diluted)
-0.14 -0.34 -0.52
EBITDA
-3.57M 279K 11.33M
EBIT
-23.11M -32.84M 3.76M
Depreciation & Amortization
8.91M 33.11M 7.57M